Patents Represented by Attorney Licata & Tyrrell P.C.
  • Patent number: 7700837
    Abstract: The present invention relates to a transformed plant cell expressing ?-amyloid gene, which is known as a causal substance of senile dementia in human, a transformed plant and a preparation method of the same, more particularly, to a transformed plant cell expressing tandem repeats of ?-amyloid gene, a transformed plant produced by tissue-culturing the above cells and a preparation method of the same. The transformed plant of the present invention expresses multiple ?-amyloid protein, so that the plant can be effectively used for the preparation of an oral vaccine composition for the prevention of senile dementia in human.
    Type: Grant
    Filed: March 11, 2004
    Date of Patent: April 20, 2010
    Assignee: Korea Research Institute of Bioscience and Biotechnology
    Inventors: Hyun Soon Kim, Jung Won Youm, Jae Heung Jeon, Mi Sun Kim, Inhee Mook, Hyouk Joung
  • Patent number: 7700544
    Abstract: Peptides and mimetics of selected domains of mammalian serum amyloid A isoform 2.1 (SAA2.1) and compounds and compositions thereof are provided that enhance the effect on macrophage cholesterol ester hydrolase activity and/or inhibit acyl CoA:cholesterol acyl transferase activity. Methods of using these compositions in the treatment and/or prevention of atherosclerosis as well as coronary heart disease and cardiovascular disease are also provided.
    Type: Grant
    Filed: November 7, 2005
    Date of Patent: April 20, 2010
    Assignee: Queens's University at Kingston
    Inventors: Robert Kisilevsky, Shui-Pang Tam, John B. Ancsin, Zongchao Jia
  • Patent number: 7691976
    Abstract: An isolated nucleic acid sequence of BRAF35 and polypeptides encoded thereby are provided, as well as a multiprotein complex, and an antibody capable of binding selectively to the BRAF35 protein. Related agents and compositions which modulate interaction between BRCA2 and BRAF35 and methods of their use for screening for the BRCA2 protein, suppressing tumors and identifying DNA damage in cells indicative of a risk for developing cancer are also provided.
    Type: Grant
    Filed: November 13, 2001
    Date of Patent: April 6, 2010
    Assignee: The Wistar Institute
    Inventor: Ramin Shiekhattar
  • Patent number: 7691833
    Abstract: Compositions and methods for preventing sporadic neoplasia of the colon are provided. The compositions provided are based on administration of acetylsalicylic acid.
    Type: Grant
    Filed: March 3, 2003
    Date of Patent: April 6, 2010
    Assignee: Trustees of Dartmouth College
    Inventor: John A. Baron
  • Patent number: 7678889
    Abstract: The present invention relates to newly identified nucleic acid molecules and polypeptides present in normal and neoplastic ovarian cells, including fragments, variants and derivatives of the nucleic acids and polypeptides. The present invention also relates to antibodies to the polypeptides of the invention, as well as agonists and antagonists of the polypeptides of the invention. The invention also relates to compositions containing the nucleic acid molecules, polypeptides, antibodies, agonists and antagonists of the invention and methods for the use of these compositions. These uses include identifying, diagnosing, monitoring, staging, imaging and treating ovarian cancer and noncancerous disease states in ovarian, identifying ovarian tissue, monitoring and identifying and/or designing agonists and antagonists of polypeptides of the invention. The uses also include gene therapy, production of transgenic animals and cells, and production of engineered ovarian tissue for treatment and research.
    Type: Grant
    Filed: August 6, 2003
    Date of Patent: March 16, 2010
    Assignee: diaDexus, Inc.
    Inventors: Roberto A. Macina, Susana Salceda, Chenghua Liu, Yongming Sun, Leah R. Turner
  • Patent number: 7674772
    Abstract: Reverse peptides and mimetics of a mammalian serum amyloid A isoform 2.1 (SAA2.1) domain or a portion thereof and compositions and pharmaceutical compositions thereof are provided that enhance the effect on macrophage cholesterol ester hydrolase activity. Methods of using these reverse peptides, mimetics thereof and compositions in the treatment and/or prevention of atherosclerosis as well as coronary heart disease and cardiovascular disease are also provided.
    Type: Grant
    Filed: March 30, 2007
    Date of Patent: March 9, 2010
    Assignee: Queen's University at Kingston
    Inventor: Perry M. Kim
  • Patent number: 7674891
    Abstract: The present invention is an isolated nucleic acid molecule encoding CD36, Gqi9, and G protein-coupled receptor 84 (GPR84) proteins as well as vectors and recombinant host cells which co-express CD36, Gqi9, and GPR84 proteins for use in identifying modulators of GPR84 activity.
    Type: Grant
    Filed: August 1, 2008
    Date of Patent: March 9, 2010
    Assignee: International Flavors & Fragrances Inc.
    Inventors: Stephen Anthony Gravina, Jason M. Montez, Hailin Wang
  • Patent number: 7666616
    Abstract: The present invention relates to genetic reporters. Specifically, the present invention is directed to a modified gene encoding a luciferase for high level expression in an organism with a bias for cytosine (C) or guanine (G) in the third position of the codon.
    Type: Grant
    Filed: September 30, 2005
    Date of Patent: February 23, 2010
    Assignees: Trustees of Dartmouth College, Regents of the University of Minnesota
    Inventors: Jay C. Dunlap, Jennifer Loros, Arun Mehra, Van D. Gooch
  • Patent number: 7662576
    Abstract: The Transient Receptor Potential Cation Channel, Subfamily A, Member 1 (TRPA1) protein has been identified as an ester cooler receptor and therefore is useful in screening assays for identifying ester coolers, in particular ester coolers with a relative cooling strength which exceeds (?)?menthol.
    Type: Grant
    Filed: December 6, 2007
    Date of Patent: February 16, 2010
    Assignee: International Flavors & Fragrances Inc.
    Inventors: Stephen Anthony Gravina, Jason Michael Montez, Vijyeta Kapur, Carrie Ann Maxwell, Mark L. Dewis
  • Patent number: 7645577
    Abstract: This invention provides isolated nucleic acids encoding polypeptides comprising amino acid sequences of streptococcal matrix adhesion (Ema) polypeptides. The invention provides nucleic acids encoding Group B streptococcal Ema polypeptides EmaA, EmaB, EmaC, EmaD and EmaE. The present invention provides isolated polypeptides comprising amino acid sequences of Group B streptococcal polypeptides EmaA, EmaB, EmaC, EmaD and EmaE, including analogs, variants, mutants, derivatives and fragments thereof. Ema homologous polypeptides from additional bacterial species, including S. pneumoniae, S. pyogenes, E. faecalis and C. diptheriae are also provided. Antibodies to the Ema polypeptides and immunogenic fragments thereof are also provided. The present invention relates to the identification and prevention of infections by virulent forms of streptococci.
    Type: Grant
    Filed: July 26, 2006
    Date of Patent: January 12, 2010
    Assignees: St. Jude Children's Research Hospital, University of Utah Research Foundation
    Inventors: Elisabeth Adderson, John Bohnsack
  • Patent number: 7638283
    Abstract: The invention described in this disclosure involves a new composition of matter, amyloid beta-derived dementing ligands (ADDL's). ADDLs consist of amyloid ? peptide assembled into soluble globular non-fibrillar oligomeric structures that are capable of activating specific cellular processes. The invention further encompasses methods for assaying the formation, presence, receptor protein binding and cellular activities of ADDLs. The invention further encompasses assay methods and inhibitor molecules for cellular signaling molecules activated by ADDLs. Also described are molecules that block proteins that promote the formation of ADDLs.
    Type: Grant
    Filed: May 16, 2005
    Date of Patent: December 29, 2009
    Assignees: Northwestern University, University of Southern California
    Inventors: Grant A. Krafft, William L. Klein, Brett A. Chromy, Mary P. Lambert, Caleb E. Finch, Todd Morgan, Pat Wals, Irina Rozovsky, Ann Barlow
  • Patent number: 7632650
    Abstract: The present invention relates to topors and its association with cancer. Topors antibodies are provided for use in diagnosing cancer based upon the absence of topors in a given cell or tissue sample. The detection of topors nucleic acid molecules in the diagnosis of cancer is also provided.
    Type: Grant
    Filed: February 5, 2007
    Date of Patent: December 15, 2009
    Assignee: University of Medicine and Dentistry of New Jersey
    Inventors: Eric H. Rubin, Ahamed Saleem, Zeshaan Rasheed, Paul Haluska, Jr.
  • Patent number: 7629123
    Abstract: Mutations located within the gene encoding the homeobox transcription factor, ENGRAILED 2 (EN2), have now been identified as molecular markers associated with susceptibility for autism and related disorders. Thus, the present invention relates to compositions in the form of diagnostic kits, primers and target sequences, for use in methods for determining the predisposition, the onset or the presence of autism spectrum disorder in a mammal. Moreover, therapeutic methods for treating a person inflicted with, or predisposed to, an autism spectrum disorder based upon modulating the level or activity of EN2 are also provided.
    Type: Grant
    Filed: January 3, 2006
    Date of Patent: December 8, 2009
    Assignees: University of Medicine and Dentistry of New Jersey, Rutgers, The State University
    Inventors: James H. Millonig, Linda Brzustowicz, Neda Gharani
  • Patent number: 7625868
    Abstract: Methods for inhibiting angiogenesis in endothelial cells and selectively inducing apoptosis in endothelial cells via compounds which binds annexin II are provided. These compounds and methods for using these compounds are useful in the treatment of diseases or disorders characterized by unwanted angiogenesis. Also provided are pharmaceutical compositions containing a compound which binds annexin II and a pharmaceutically acceptable vehicle and methods for identifying such compounds.
    Type: Grant
    Filed: January 5, 2007
    Date of Patent: December 1, 2009
    Assignee: Philadelphia, Health and Education Corporation
    Inventors: Mahesh C. Sharma, George P. Tuszynski
  • Patent number: 7625561
    Abstract: Common oral diseases such as periodontitis and dental caries can be prevented effectively by passive immunization. The present invention provides human single chain Fv (scFv) and diabody antibody fragments based on the binding characteristics of the murine monoclonal antibody Guy's 13. Like the parent antibody, these derivatives bind specifically to SAI/II, the surface adhesin of Streptococcus and the human diabody derivative is capable of aggregating streptococcal cells, making it a useful candidate therapeutic agent for passive immunization against oral diseases.
    Type: Grant
    Filed: April 21, 2005
    Date of Patent: December 1, 2009
    Assignee: Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.
    Inventors: Ricarda Finnern, Rainer Fischer
  • Patent number: 7618782
    Abstract: A method for assessing muscle damage in a biological sample obtained from a subject is disclosed. The method involves obtaining a biological sample from a subject being assessed for muscle damage, and evaluating the sample for the presence or absence of a myofilament protein modification product. Preferably, the myofilament protein modification product is a chemical adduct of a myofilament protein. The method can also be used to assess the extent and/or type of muscle damage in a subject by studying the profile of myofilament protein modification products detected in the sample taken from the subject. The invention further provides a method for screening for an agent which modulates the level of a myofilament protein modification product an present in a biological sample or for a calcium sensitizing agent. The invention is applicable to cardiac muscle and skeletal muscle.
    Type: Grant
    Filed: October 18, 1999
    Date of Patent: November 17, 2009
    Assignee: Queen's University at Kingston
    Inventors: Jennifer E. Van Eyk, Ralf Labugger, Irena Neverova
  • Patent number: 7615308
    Abstract: Dual function, bipolar separator plates are provided for use in fuel cells. These separator plates contain both a cathodic flow field and an anodic flow field in a single separator plate.
    Type: Grant
    Filed: March 3, 2005
    Date of Patent: November 10, 2009
    Assignee: IRD Fuel Cells A/S
    Inventors: Henning Frederiksen, Steen Yde-Andersen, Laila Grahl-Madsen, Joergen Schjerning Lundsgaard
  • Patent number: 7598238
    Abstract: Fused-ring triazole compounds which inhibit proliferation of cells and exhibit a unique and intense fluorescence are provided. Also provided are methods for synthesizing these compounds and methods for using these compounds to inhibit cell proliferation and infection and to label and fluorescently detect selected molecules.
    Type: Grant
    Filed: July 28, 2006
    Date of Patent: October 6, 2009
    Assignees: University of Medicine and Dentistry of New Jersey, Rutgers, the State University, Lehigh University
    Inventors: Jeffrey D. Laskin, Ned Heindel, Diane Heck, Anna Marie Vetrano, Christophe Guillon, Peter DeMatteo
  • Patent number: 7595194
    Abstract: Multipotent neuroepithelial stem cells and lineage-restricted oligodendrocyte-astrocyte precursor cells are described. The neuroepithelial stem cells are capable of self-renewal and of differentiation into neurons, astrocytes, and oligodendrocytes. The oligodendrocyte-astrocyte precursor cells are derived from neuroepithelial stem cells, are capable of self-renewal, and can differentiate into oligodendrocytes and astrocytes, but not neurons. Methods of generating, isolating, and culturing such neuroepithelial stem cells and oligodendrocyte-astrocyte precursor cells are also disclosed.
    Type: Grant
    Filed: May 1, 2006
    Date of Patent: September 29, 2009
    Assignee: University of Utah Research Foundation
    Inventors: Mahendra S. Rao, Margot Mayer-Proschel
  • Patent number: 7588773
    Abstract: The present invention provides a group B streptococcal (GBS) surface antigen, designated epsilon antigen, that is co-expressed with the delta antigen on a subset of serotype III GBS. Epsilon is expressed on more pathogenic Restriction Digest Pattern (RDP) III-3 GBS, but not on RDP types 1, 2, or 4. Accordingly, the present invention provides compositions and methods for detecting a group B streptococcus serotype III, RDP III-3 strain. Vaccines and methods of identifying agents which inhibit adhesion of a group B streptococcal cell to a host cell are also provided.
    Type: Grant
    Filed: August 19, 2005
    Date of Patent: September 15, 2009
    Assignees: St. Jude Children's Research Hospital, University of Florida, University of Utah Research Foundation
    Inventors: Linda Jeannine Brady, Kyle N. Seifert, Elisabeth E. Adderson, John F. Bohnsack